Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin-2 gene therapy (VCL-IM01)

Drug Profile

Interleukin-2 gene therapy (VCL-IM01)

Alternative Names: Electroporation-delivered DNA immunotherapy against metastatic melanoma - Inovio/Vical; IL-2 plasmid DNA/lipid complex (Leuvectin); IL-2-based DNA vaccine - Vical; IL-2/EP - Vical; Interleukin-2 gene therapy - Vical; VCL-1M01; VCL-IM01

Latest Information Update: 20 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Developer Inovio Pharmaceuticals; Vical
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Gene transference; Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer

Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer; Renal cancer

Most Recent Events

  • 18 Dec 2008 Final efficacy and adverse events data from a phase I trial in Metastatic melanoma presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)
  • 11 Jun 2007 Interim results from a phase I clinical trial in patients with Metastatic melanoma added to the adverse events and Cancer therapeutic trials sections
  • 27 Jul 2005 Phase-I clinical trials in Metastatic melanoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top